Scotia Capital Inc. Ab Cellera Biologics Inc. Transaction History
Scotia Capital Inc.
- $19.9 Billion
- Q2 2025
A detailed history of Scotia Capital Inc. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Scotia Capital Inc. holds 29,024 shares of ABCL stock, worth $170,370. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,024
Previous 16,071
80.6%
Holding current value
$170,370
Previous $35,000
182.86%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ABCL
# of Institutions
149Shares Held
115MCall Options Held
488KPut Options Held
476K-
Baker Bros. Advisors LP New York, NY27.5MShares$162 Million0.96% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$78.4 Million0.01% of portfolio
-
Baillie Gifford & CO10.4MShares$60.8 Million0.03% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL8.47MShares$49.7 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$26.7 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.67B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...